Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer | NEJM
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Annals of Oncology
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 - Annals of Oncology
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study - Annals of Oncology
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer | NEJM
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Breast cancer - The Lancet
Chemo or Hormone Therapy Result in Similar Survival for Women with Breast Cancer - CancerConnect
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy | Anticancer Research
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer - The Lancet Oncology
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence: Trends in Cancer
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium - Annals of Oncology
